dc.contributor.author
Dakterzada, Farida
dc.contributor.author
Jové Font, Mariona
dc.contributor.author
Cantero, José Luís
dc.contributor.author
Mota Martorell, Natàlia
dc.contributor.author
Pamplona Gras, Reinald
dc.contributor.author
Piñol Ripoll, Gerard
dc.date.issued
2024-03-27
dc.identifier
https://doi.org/10.1002/alz.13792
dc.identifier
https://hdl.handle.net/10459.1/465639
dc.description.abstract
Introduction: Fatty acids (FAs) are the building blocks of complex lipids and signaling compounds; the role of the lipidome fatty acid profile (LFA) in AD progression remains unclear. Methods: The LFA of plasma and cerebrospinal fluid (CSF) samples from 289 participants (103 AD patients, 92 MCI patients, and 94 controls) was determined by GC-FID. The MCI subjects were followed up for 58 ± 12.5 months. Results: In controls, CSF has a more neuroprotective LFA than plasma. In CSF, a higher content of docosahexaenoic acid was associated with a reduced risk of MCI-to-AD progression. In plasma, higher oleic acid content was associated with lower risk of AD, MCI, and MCI-to-AD progression, whereas higher levels of vaccenic acid and docosahexaenoic acid were associated with greater risk of AD and MCI, and higher rate of MCI-to-AD progression, respectively. Discussion: The circulating LFA is involved in the pathogenesis and progression of AD. Highlights: The lipidome fatty acid profile in CSF and plasma was markedly different. Higher levels of vaccenic acid and lower levels of oleic acid in plasma were associated with greater risk of Alzheimer's disease. In plasma, higher levels of oleic acid were associated with a reduced risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in CSF were associated with a lower risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in plasma were associated with a greater rate of MCI-to-AD progression.
dc.description.abstract
Government of Catalonia,Grant/Award Number:PERIS 2019 SLT008/18/00050; Ministerio de Ciencia, Innovación y Universidades; European Union ’Awaytobuild Europe’, Grant/Award Numbers: RTI2018-099200-B-I00, PID2023-152233OB-I00; Diputació de Lleida, Grant/Award Number: PP10605-PIRS2021; Spanish Ministry of Economy and Competitiveness, Grant/Award Number: PID2020-119978RB-I00; CIBERNED, Alzheimer’s Association, Grant/Award Number:AARG-NTF-22-924702; Junta de Andalucía, Grant/Award Number: PY20_00858; Andalucía-FEDER Program, Grant/Award Number: UPO-1380913; Agency for Management of University and Research Grants, Grant/Award Number: 2021SGR 00761; Agency for Management of University and Research Grants and the European Social Fund, Grant/Award Number: FI_B100153; Agency for Management of University and Research Grants and the European Social Fund, Grant/Award Number: 2021SGR00990
dc.format
application/pdf
dc.publisher
Wiley Periodicals
dc.relation
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-099200-B-I00/ES/NEUROLIPIDOMICA DEL ENVEJECIMIENTO CEREBRAL HUMANO/
dc.relation
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-119978RB-I00/ES/ESTUDIO DEL DETERIORO DE LA ORIENTACION ESPACIAL COMO FACTOR DE RIESGO DE LA ENFERMEDAD DE ALZHEIMER EN PERSONAS MAYORES CON QUEJAS SUBJETIVAS DE MEMORIA/
dc.relation
Reproducció del document publicat a: https://doi.org/10.1002/alz.13792
dc.relation
Alzheimers & Dementia, 2024
dc.rights
cc-by-nc (c) The Authors, 2024
dc.rights
info:eu-repo/semantics/openAccess
dc.rights
https://creativecommons.org/licenses/by-nc/4.0
dc.subject
Alzheimer's disease
dc.subject
Anti‐inflammatory index
dc.subject
Cerebrospinal fluid
dc.subject
Docosahexaenoic acid
dc.subject
Mild cognitive impairment
dc.subject
Peroxidation index
dc.title
The shift in the fatty acid composition of the circulating lipidome in Alzheimer's disease
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion